Atlas Genetics Ltd.

BRISTOL, England, July 20, 2011 - Funds to Accelerate Launch of Velox™ Point-of-care Test for Chlamydia and Gonorrhoea Atlas Genetics Ltd ("Atlas" or the "Company"), a diagnostic company developing ultra-rapid point-of-care tests for a range of infectious diseases, announces that it has raised 16.9 million from a syndicate of new and existing investors led by Novartis Venture Funds, and Consort Medical plc.